Prurigo Nodularis onset during secukinumab treatment of psoriasis: a case report

[1] Varshney P(2016)Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis Sci Rep 6 19295-202

[2] Jaleel T(2016)Secukinumab (AIN-457) for the treatment of Psoriasis Expert Rev Clin Pharmacol 9 187-98

[3] van de Kerkhof PC(2016)Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis J Am Acad Dermatol 75 83-20

[4] Blauvelt A(2016)Safety of secukinumab in the treatment of psoriasis Expert Opin Drug Saf 15 1413-21

[5] Papp KA(2013)Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study Br J Dermatol 168 412-9

[6] Reich K(2019)Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial Lancet 394 831-12

[7] Cozzani E(2010)The quality of life in italian psoriatic patients treated with biological drugs G Ital Dermatol Venereol 145 709-2218e14

[8] Belzberg M(2021)Prurigo Nodularis is characterized by systemic and cutaneous T helper 22 Immune polarization J Invest Dermatol 141 2208-40

[9] Zeidler C(2016)The pathogenesis of Prurigo nodularis–‘Super-Itch’ in exploration Eur J Pain 20 37-7

[10] Stander S(2019)Atopic-like dermatitis after secukinumab injection: a case report Dermatol Ther 32 e12751-6

[1] Varshney P(2016)Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis Sci Rep 6 19295-202

[2] Jaleel T(2016)Secukinumab (AIN-457) for the treatment of Psoriasis Expert Rev Clin Pharmacol 9 187-98

[3] van de Kerkhof PC(2016)Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis J Am Acad Dermatol 75 83-20

[4] Blauvelt A(2016)Safety of secukinumab in the treatment of psoriasis Expert Opin Drug Saf 15 1413-21

[5] Papp KA(2013)Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study Br J Dermatol 168 412-9

[6] Reich K(2019)Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial Lancet 394 831-12

[7] Cozzani E(2010)The quality of life in italian psoriatic patients treated with biological drugs G Ital Dermatol Venereol 145 709-2218e14

[8] Belzberg M(2021)Prurigo Nodularis is characterized by systemic and cutaneous T helper 22 Immune polarization J Invest Dermatol 141 2208-40

[9] Zeidler C(2016)The pathogenesis of Prurigo nodularis–‘Super-Itch’ in exploration Eur J Pain 20 37-7

[10] Stander S(2019)Atopic-like dermatitis after secukinumab injection: a case report Dermatol Ther 32 e12751-6